<DOC>
	<DOCNO>NCT00136955</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Irinotecan plus cisplatin first-line chemotherapy advance recurrent cervical cancer</brief_summary>
	<brief_title>Irinotecan Study For Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically document , advanced recurrent squamous cell carcinoma uterine cervix . Patients may receive concurrent ( radiotherapy ) ( neo ) adjuvant ( local treatment ) chemotherapy primary tumor provide least 6 month pass completion previous therapy diagnosis recurrent disease document Having measurable lesion ( ) , without previous radiation therapy . Patients ever receive primary chemotherapy cervical cancer mention previously ( inclusion criterion ) . Patients ever receive cisplatin total dose &gt; 300 mg/m2 receive radiotherapy local treatment deliver target lesion .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Weekly Irinotecan ( 60mg/sqm , D1 , 8 , 15 ) combination Cisplatin ( 60mg/sqm , D1 ) , Squamous Cell Carcinoma Of The Uterine Cervix</keyword>
</DOC>